NCT03642561Unknown2 期
Liver Cancer Institiute ,Fudan University
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- overall survival
研究概览
简要总结
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
详细描述
The investigators conduct this clinical trial to evaluate the treatment outcome of RFA in HCC patients with tumor smaller than 7cm and tumor number less than five ,in comparison with TACE treatment.The primary outcome is overall survival.The secondary outcome is objective response rate.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
overall survival
时间窗: up to 60 months
次要结局
- objective response rate(up to 60 months)
研究者
Zheng-Gang Ren
zhongshan hospital
Fudan University
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation (RFA) Associated With Postoperative TACECancer of LiverNCT00730860Southwest Hospital, China140
招募中
4 期
Tenofovir Alafenamide(TAF) Reduces the Risk of Hepatocellular Carcinoma(HCC) RecurrenceHCC Patients After Curative Treatment With Low HBV Viral LoadNCT04290936Taipei Veterans General Hospital, Taiwan402
终止
2 期
Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT GenotypeHepatocellular CarcinomaNCT03608878Chang Gung Memorial Hospital5
终止
2 期
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.Hepatocellular CarcinomaNCT05171166Peking University18
已完成
1 期
Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCCRapamycinHepatocellular CarcinomaNCT02724332Eastern Hepatobiliary Surgery Hospital300